PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or advanced s...

Descripción completa

Detalles Bibliográficos
Autores principales: Risnayanti, Chitra, Jang, Yeong-Su, Lee, Jinju, Ahn, Hyung Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951813/
https://www.ncbi.nlm.nih.gov/pubmed/29760419
http://dx.doi.org/10.1038/s41598-018-25930-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951813/
https://www.ncbi.nlm.nih.gov/pubmed/29760419
http://dx.doi.org/10.1038/s41598-018-25930-7

Ejemplares similares